PROCEPT BioRobotics (NASDAQ:PRCT) and Revolutions Medical (OTCMKTS:RMCP) Critical Analysis

Revolutions Medical (OTCMKTS:RMCP) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Revolutions Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolutions Medical	N/A	N/A	N/A
PROCEPT BioRobotics	-58.73%	-37.85%	-26.20%

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 10.5% of Revolutions Medical shares are owned by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Revolutions Medical and PROCEPT BioRobotics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolutions Medical	N/A	N/A	N/A	N/A	N/A
PROCEPT BioRobotics	$176.58 million	23.16	-$105.90 million	($2.12)	-37.51

Revolutions Medical has higher earnings, but lower revenue than PROCEPT BioRobotics.

Analyst Ratings

This is a summary of current recommendations and price targets for Revolutions Medical and PROCEPT BioRobotics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolutions Medical	0	0	0	0	N/A
PROCEPT BioRobotics	0	0	7	0	3.00

PROCEPT BioRobotics has a consensus price target of $78.17, indicating a potential downside of 1.70%. Given PROCEPT BioRobotics’ higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Revolutions Medical.

Risk & Volatility

Revolutions Medical has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Summary

PROCEPT BioRobotics beats Revolutions Medical on 6 of the 9 factors compared between the two stocks.

About Revolutions Medical

Revolutions Medical Corporation, a development stage company, is engaged in the design, development, and commercialization of auto retractable vacuum safety syringes in the United States and internationally. The company develops RevVac auto retractable vacuum safety syringe, which is designed to reduce accidental needle stick injuries and lower the spread of blood borne diseases. It is also developing a suite of magnetic resonance imaging software tools consisting of RevColor, Rev3D, RevDisplay, and RevScan that are designed to enhance general diagnostic confidence through education and research use. The company sells its products to acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons through distributors. Revolutions Medical Corporation was founded in 1996 and is headquartered in Charleston, South Carolina.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.